Target Interacting Protein Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T83009 | Target Info | |||
Target Name | Tyrosine-protein kinase ABL2 (ABL2) | ||||
Synonyms | Tyrosine-protein kinase ARG; Abelson-related gene protein; Abelson tyrosine-protein kinase 2; Abelson murine leukemia viral oncogene homolog 2; ARG; ABLL | ||||
Target Type | Literature-reported Target | ||||
Gene Name | ABL2 | ||||
Biochemical Class | Kinase | ||||
UniProt ID |
Target Interacting Proteins | Top | ||||
---|---|---|---|---|---|
Kinases | [+] 3 Kinases | + | |||
Interacting Target Name | Epidermal growth factor receptor (EGFR) | Successful Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Epidermal growth factor receptor variant III; Proto-oncogene c-ErbB-1 variant III; Receptor tyrosine-protein kinase erbB-1 variant III; EGFR variant III; ERBB variant III; ERBB1 variant III; HER1 variant III | ||||
Evidence Score (E-score) | 3 Experimental Evidences | + | |||
1 | Protein-Fragment Complementation Assay | [1] | |||
2 | Protein-peptide | [2] | |||
3 | Yeast two hybrid | [3] | |||
Interacting Target Name | Tyrosine-protein kinase ABL1 (ABL) | Successful Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Proto-oncogene tyrosine-protein kinase ABL1; Proto-oncogene c-Abl; p150; JTK7; C-ABL; Abl; Abelson tyrosine-protein kinase 1; Abelson murine leukemia viral oncogene homolog 1 | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Affinity Capture-Western | [4] | |||
2 | Reconstituted Complex | [4] | |||
Interacting Target Name | Erbb2 tyrosine kinase receptor (HER2) | Successful Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | Tyrosine kinase-type cell surface receptor HER2; Tyrosine kinase receptor ErbB2; Receptor tyrosine-protein kinase erbB-2; Proto-oncogene Neu; Proto-oncogene c-ErbB-2; P185erbB2; NGL; NEU proto-oncogene; NEU; MLN19; MLN 19; Metastatic lymph node gene 19 protein; HER2/neu; HER2 (erbB2/neu); HER-2; Erb2; Epidermal growth factor receptor 2; C-erbB-2 oncoprotein; C-erbB-2; CD340 | ||||
Evidence Score (E-score) | 2 Experimental Evidences | + | |||
1 | Far Western | [5] | |||
2 | Protein-peptide | [2] | |||
Other proteins | [+] 1 Other proteins | + | |||
Interacting Target Name | Proto-oncogene c-Crk (c-Crk) | Literature-reported Target | Interacting Protein Info | ||
UniProt ID | |||||
Synonyms | P38; Adapter molecule crk | ||||
Evidence Score (E-score) | 5 Experimental Evidences | + | |||
1 | Affinity Capture-MS | [6] | |||
2 | Biochemical Activity | [7] | |||
3 | Biochemical Activity | [8] | |||
4 | Reconstituted Complex | [7] | |||
5 | Yeast two hybrid | [9] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells. Nat Methods. 2014 May;11(5):585-92. | ||||
REF 2 | A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature. 2006 Jan 12;439(7073):168-74. | ||||
REF 3 | In silico prediction of physical protein interactions and characterization of interactome orphans. Nat Methods. 2015 Jan;12(1):79-84. | ||||
REF 4 | Functional interaction between the c-Abl and Arg protein-tyrosine kinases in the oxidative stress response. J Biol Chem. 2003 Apr 11;278(15):12961-7. | ||||
REF 5 | Reciprocal regulation of Abl and receptor tyrosine kinases. Cell Signal. 2009 Jul;21(7):1143-50. | ||||
REF 6 | Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci U S A. 2009 May 5;106(18):7414-9. | ||||
REF 7 | c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J. 1994 May 15;13(10):2341-51. | ||||
REF 8 | RIN1 is an ABL tyrosine kinase activator and a regulator of epithelial-cell adhesion and migration. Curr Biol. 2005 May 10;15(9):815-23. | ||||
REF 9 | Phospho-tyrosine dependent protein-protein interaction network. Mol Syst Biol. 2015 Mar 26;11(3):794. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.